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Letter to the Editor: 
We appreciate the excellent review of Carpio, Esco- 
bar, and Hauser (1) about the relationship between cys- 
ticercosis and epilepsy, and their emphasis on the crucial 
difference between acute and remote symptomatic sei- 
zures (2). This is particularly true when a single cerebral 
cysticercus granuloma is diagnosed. In our experience 
(eight cases of single cysticercus granuloma with acute 
symptomatic seizures), we never observed later epilepsy. 
In these patients, antiepileptic drugs (AEDs) were dis- 
continued successfully after a few months (3). 
However, some aspects related to the prognosis of 
epilepsy secondary to neurocysticercosis need further 
comment. This form of remote symptomatic epilepsy is 
described classically as a “benign condition” easily con- 
trolled by AEDs. Although data in support of this are 
rare, our report on 143 patients with epilepsy due to 
neurocysticercosis (3) (including eight patients with 
single cystcercus granulomas and acute symptomatic sei- 
zures, and 24 with one or more calcifications and a single 
symptomatic remote seizure) with a mean follow-up pe- 
riod of 5 years (finishing in 1993) reinforce this conclu- 
sion. At the time of our data analysis, 66% of patients (n = 
97) had achieved remission (no seizures in the last 2 years). 
Patients not in remission (n = 46) were reevaluated 3 
years later. Seventeen of three patients had remitted sub- 
sequently; 10 remained uncontrolled, and the condition 
of 19 was unknown. Assuming that these 19 patients still 
have seizures, 29 patients (20%) in the series were un- 
controlled. The majority of such patients have sporadic 
minor complex partial seizures (CPS) that have only lim- 
ited impact on their quality of life. They also live far from 
our outpatient clinic, which creates difficulties for regular 
clinical and drug monitoring, 
We consider the overall prognosis of all seizures due 
parenchymatous neurocysticercosis to be as good or bet- 
ter than that of epilepsy in general. The remission rate is 
high (80%), if follow-up is long enough and medical 
treatment is continued. 
Prospective cohort studies are difficult in developing 
countries with scarce health facilities, difficult travel 
conditions, and drugs too expensive for many people. 
Our experience with neurocysticercosis is from Portugal, 
a European Union country with rich urban areas and 
some rural but underdeveloped regions. We have a stmc- 
tured National Health Service (NHS) that provides full 
medical assistance, shared transportation, and AEDs. In 
such conditions a coherent and long-term treatment 
of a chronic condition such as epilepsy is more likely 
to be successful than in developing countries. Compari- 
sons of results of treatments of a chronic disease that 
have not taken into account the effects of adverse medi- 
cal care environments might create problems in interpret- 
ing data. 
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REPLY 
To the Editor: 
We thank Monteiro and colleagues for their comments 
on our article concerning the relationship between neu- 
rocystercosis (NC) and epilepsy. We agree that seizures 
in patients with NC have a prognosis similar to that 
reported in studies of recurrence after a first unprovoked 
seizure. 
In a clinical trial of treatment of patients with newly 
identified active neurocysticercosis to evaluate the effi- 
cacy of two antihelminthic drugs (albendazole and prazi- 
quantel) against each other and against symptomatic 
treatment alone ( I ) ,  at 2 years of follow-up, we found no 
differences in proportion of individual patients who were 
free of cysts, and the proportion of patients presenting 
with seizures who were free of seizures (around 60%) 
was similar in all treatment arms. Not surprisingly, this 
proportion is similar to that reported (66%) for Monteiro 
et al. (2). 
A recent prospective cohort study to evaluate the risk 
of seizure recurrence after a first seizure due to NC was 
performed (3). Twenty-four patients (34%) experienced 
one or more incidents of seizure recurrence. The cumu- 
lative estimate of recurrence was 18% at 6 months, 28% 
at 12 months, 33% at 24 months, and 48% at 48 months. 
There was no statistically significant differences in the 
Kaplan-Meier curves of recurrence between the group 
who received treatment with albendazole in comparison 
with the group of patients who only received symptom- 
atic treatment. 
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